Ilaris (Canakinumab)

Canakinumab is a fully human monoclonal antibody that binds specifically to interleukin‑1β, a key cytokine in the inflammatory cascade. By neutralizing IL‑1β, the drug prevents activation of the interleukin‑1 receptor, thereby blocking downstream signaling that leads to production of other pro‑inflammatory mediators such as IL‑6 and C‑reactive protein, reducing systemic inflammation.

The dose of Ilaris is individualized by the prescribing clinician based on the specific indication, patient weight, disease severity and response to therapy. Dosing regimens may vary between conditions such as CAPS, SJIA or gout, and are typically administered as a subcutaneous injection at intervals determined by the treating physician.

Canakinumab’s pregnancy category is unknown, and limited data are available on its use in pregnant or nursing women. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and risk considerations with their healthcare provider.

To request Ilaris, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, cold‑chain shipping details (if required) and assists with import documentation.

The main alternative IL‑1 targeting agents are anakinra, an IL‑1 receptor antagonist, and rilonacept, a soluble decoy receptor. Canakinumab differs by being a monoclonal antibody with a longer half‑life, allowing less frequent dosing (typically every 4–8 weeks) compared with daily anakinra injections. Efficacy and safety profiles vary by indication, and choice depends on disease, patient preference and clinical response.

Ilaris should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes before administration.

Ilaris is supplied as a sterile solution for subcutaneous injection. The injection is performed by a qualified healthcare professional, typically into the abdomen, thigh or upper arm. The volume administered corresponds to the prescribed dose, and the injection site should be rotated to reduce local reactions.

The most serious risks include severe or opportunistic infections, neutropenia (low neutrophil count), hypersensitivity reactions that can be life‑threatening, gastrointestinal perforation, and rare reports of malignancy. Patients should be monitored regularly for signs of infection, blood count changes and any unexpected symptoms.

Ilaris is contraindicated in patients with known hypersensitivity to canakinumab or any component of the formulation. It should be avoided in individuals with active, uncontrolled infections, and caution is advised in those with a history of recurrent infections, severe neutropenia, or who are receiving other potent immunosuppressants.